28 Feb 2023
ATAGI recommendations on use of the Moderna bivalent (Original/Omicron BA.4/5) COVID-19 vaccine
Recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI) on the use of the Moderna bivalent (Original/Omicron BA.4/5) COVID-19 vaccine.
28 Feb 2023
ATAGI recommendations on use of the Moderna bivalent (Original/Omicron BA.4/5) COVID-19 vaccine
Recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI) on the use of the Moderna bivalent (Original/Omicron BA.4/5) COVID-19 vaccine.
28 Feb 2023
ATAGI recommendations on use of the Moderna bivalent (Original/Omicron BA.4/5) COVID-19 vaccine
Recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI) on the use of the Moderna bivalent (Original/Omicron BA.4/5) COVID-19 vaccine.
27 Feb 2023
This clinical trial is testing a new cure for a deadly rare blood cancer
In 2018 Scott Griffiths developed a deadly rare blood cancer in his brain. He believed he was going to die. But a new precision medicine developed by his doctor Professor Maher Gandhi cured Scott. Maher is conducting a clinical trial to test if his new treatment works for other patients
27 Feb 2023
This clinical trial is testing a new cure for a deadly rare blood cancer
In 2018 Scott Griffiths developed a deadly rare blood cancer in his brain. He believed he was going to die. But a new precision medicine developed by his doctor Professor Maher Gandhi cured Scott. Maher is conducting a clinical trial to test if his new treatment works for other patients
27 Feb 2023
This clinical trial is testing a new cure for a deadly rare blood cancer
In 2018 Scott Griffiths developed a deadly rare blood cancer in his brain. He believed he was going to die. But a new precision medicine developed by his doctor Professor Maher Gandhi cured Scott. Maher is conducting a clinical trial to test if his new treatment works for other patients
27 Feb 2023
Engaging childhood brain cancer survivors
Over 90% of childhood brain cancer survivors develop life threatening and disabling health conditions after they finish cancer treatment. Engage is a consumer co-designed telehealth trial that helps these survivors manage their health and improve their quality of life
27 Feb 2023
Engaging childhood brain cancer survivors
Over 90% of childhood brain cancer survivors develop life threatening and disabling health conditions after they finish cancer treatment. Engage is a consumer co-designed telehealth trial that helps these survivors manage their health and improve their quality of life
27 Feb 2023
Engaging childhood brain cancer survivors
Over 90% of childhood brain cancer survivors develop life threatening and disabling health conditions after they finish cancer treatment. Engage is a consumer co-designed telehealth trial that helps these survivors manage their health and improve their quality of life
24 Feb 2023
Inviting all research administration officers to our next webinar
We invite all research administration officers (RAOs) to join our next Medical Research Future Fund (MRFF) RAO Webinar at 2:00pm (AEDT) on 30 March 2023